What TILT Biotherapeutics does

TILT Biotherapeutics Oy is a clinical-stage biotechnology company founded in 2013 and headquartered at the Biomedicum research centre in Helsinki, Finland, with a U.S. operating subsidiary (TiltBio Inc) established in 2026 in West Palm Beach, Florida. The company develops a proprietary oncolytic adenoviral immunotherapy platform branded TILT®, which engineers viruses to deliver immunostimulatory cytokines (TNF and IL-2) into the tumor microenvironment to convert immunologically "cold" solid tumors into "hot" tumors and enhance T-cell-mediated immune responses. Its lead asset, TILT-123 (igrelimogene litadenorepvec), is the only engineered oncolytic virus armed with both TNF and IL-2, is administered intravenously, has completed Phase I trials in approximately 100 patients with a clean safety profile, and is Phase II ready for front-line treatment of recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC). The broader pipeline includes preclinical Ad5/3 chimeric constructs TILT-321/322 (Muc1 bispecific antibody) and TILT-234 (Ad3-CD40L dendritic-cell enabling technology).

TILT generates revenue exclusively through non-commercial channels: licensing and partnership agreements with pharmaceutical companies (Merck & Co. for pembrolizumab combinations in ovarian and lung cancer; Merck KGaA for avelumab combinations in melanoma and head and neck cancer), milestone payments from clinical progress, and non-dilutive grants such as a USD 2M U.S. Department of Defense award for ovarian cancer research. The go-to-market model is enterprise clinical collaboration rather than direct sales, leveraging scientific publications and conference presence (ASCO, ESMO) to position combination-therapy data for partners. The company has raised more than €70M since inception (approximately 75% equity, 25% non-dilutive), including a USD 25.6M Series B in May 2025 led by the European Innovation Council Fund. In 2026 the group reorganized into a holding structure with TiltBio Inc advancing late-stage TILT-123 in the U.S. and Kaira Therapeutics Oy housing early-stage discovery assets, supported by Litagene Oy which retains TILT-123 IPR and CMC.

Name

TILT Biotherapeutics

Legal name

TILT Biotherapeutics Oy

Website

https://tiltbio.com

Company type

Private

Founded year

2013

Operating status

Operating

Headcount range

11–50 employees

Short description

TILT Biotherapeutics is a Helsinki-based clinical-stage biotech developing the TILT® oncolytic adenoviral immunotherapy platform, with lead asset TILT-123 (a TNF/IL-2-armed virus) in Phase II for solid tumors including front-line R/M HNSCC. The company generates revenue through pharma licensing and non-dilutive grants rather than product sales.

Ownership category

akta.pro rank

Product category

Oncology Immunotherapy

NAICS

Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Oncology Gene Therapies (incl. oncolytic vectors & gene-modified approaches) (HLAAACAF)

Keywords

• Oncolytic immunotherapy
• Solid tumor therapy
• Adenoviral cancer treatment
• Cytokine-armed viruses
• Tumor microenvironment modulation

Headquarters

HQ city

Helsinki

HQ country

Finland

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Licensing and Partnership Revenue: TILT generates revenue through strategic partnerships with pharmaceutical companies for combination therapy development, licensing agreements for TILT® technology, and milestone payments from clinical development progress.
2. Non-dilutive Funding: The company has secured grant funding from government sources including U.S. Department of Defense for specific research programs such as the $2M ovarian cancer immunotherapy project.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels4 records

Core offering

TILT Biotherapeutics develops investigational oncolytic adenoviral immunotherapies for solid tumors based on its patented TILT® technology platform. The core offering is TILT-123 (igrelimogene litadenorepvec), a Phase II-ready intravenously delivered cytokine-armed adenovirus armed with two immunostimulatory cytokines (TNF and IL-2) designed to modify the tumor microenvironment, converting immunologically cold tumors into hot tumors to enhance immune responses. The company also has preclinical assets TILT-321, TILT-322, and TILT-234 in its pipeline.

Product overview

TILT Biotherapeutics is a clinical-stage biotechnology company with a portfolio of oncolytic adenoviral immunotherapies for solid tumors. The core offering is the TILT® technology platform, a patented oncolytic virus technology that modifies the tumor microenvironment to enable T-cell therapies. The lead product is TILT-123 (igrelimogene litadenorepvec), a Phase II-ready intravenously delivered adenovirus armed with two immunostimulatory cytokines (TNF and IL-2). The pipeline includes early-stage assets TILT-321/322 (bispecific antibody-armed constructs for solid tumors) and TILT-234 (dendritic-cell therapy enabling technology). In 2026, the company reorganized into spin-out entities: TiltBio Inc (U.S.) for late-stage TILT-123 development in head and neck cancer, and Kaira Therapeutics Oy (Europe) for early-stage discovery assets.

Differentiator

Problem solved

Functional benefit

Products and services

• TILT-123 (igrelimogene litadenorepvec) Phase II-ready intravenously delivered cytokine-armed adenoviral immunotherapy for solid tumors, designed with dual selectivity for tumor replication using a chimeric adenovirus armed with TNF and IL-2 cytokines. Intended for patients with solid tumors such as ovarian cancer, melanoma, head and neck squamous cell carcinoma (HNSCC), and lung cancer.
• TILT® technology platform Proprietary oncolytic virus technology platform based on adenoviral vectors that encode immunostimulatory cytokines to modify the tumor microenvironment, enabling T-cell therapy for solid tumors. Licensed to pharmaceutical companies for combination therapy development.
• TILT-321 and TILT-322 Preclinical-stage Ad5/3 chimeric oncolytic adenoviruses armed with bispecific antibody against Muc1 for solid tumors, enabling T-cell recruitment into tumors and local activation through local delivery of cytokine and/or bispecific antibody.
• TILT-234 Preclinical enabling technology for dendritic-cell therapy based on Adenovirus serotype 3 (Ad3) genome armed with human CD40L. Available for out-licensing to third parties.

Quantifiable outcome

• Clean safety profile established with approximately 100 patients treated across Phase I trials
• +2 more outcomes

Named customers1 record

Segments2 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Three partnerships are on record, tiered core.

• Merck & Co., Inc. (US)coreStrategic or Co-development PartnerClinical collaboration for pembrolizumab (KEYTRUDA®) in ovarian and lung cancer studies using TILT-123. Partnership aimed at generating data on combination therapy potential.
• Merck KGaA (Germany)coreStrategic or Co-development PartnerClinical collaboration for avelumab (BAVENCIO®) in combination with TILT-123 for melanoma and head and neck cancer studies.
• Mayo CliniccoreStrategic or Co-development PartnerClinical collaboration for ovarian cancer treatment research using TILT-123, focusing on patients with platinum-resistant/refractory ovarian cancer.

Scale indicators7 records

Recent moves9 records

Expansion highlights6 records

Direct peers

• Oncolytics Biotech: Canadian clinical-stage company developing pelareorep, an intravenously delivered oncolytic reovirus for solid tumors including breast cancer and multiple myeloma. Comparable systemic-delivery oncolytic virus platform with checkpoint inhibitor combination strategy.
• CG Oncology (Cold Genesys): US clinical-stage biotech developing cretostimogene grenadenorepvec, an oncolytic adenovirus for bladder cancer. Comparable modality (oncolytic adenovirus for solid tumors) with direct overlap in mechanism and development stage.
• Transgene: French clinical-stage biotech developing oncolytic virus immunotherapies (TG4001, TG6002) and therapeutic cancer vaccines. Comparable modality with overlap in solid tumor indications and combination immunotherapy approach.
• SillaJen: Korean/US clinical-stage biotech developing pexastimogene devacirepvec (Pexa-Vec), an oncolytic vaccinia virus for solid tumors including hepatocellular carcinoma. Comparable modality (oncolytic virus immunotherapy) and combination checkpoint inhibitor strategy.
• Targovax: Norwegian clinical-stage immuno-oncology company developing oncolytic viruses (formerly Oncos Therapeutics, co-founded by TILT founder Akseli Hemminki). Directly comparable platform technology targeting solid tumors, with similar modality and indication overlap. Public company with disclosed financials.
• PsiOxus Therapeutics: UK-based clinical-stage biotech developing oncolytic virus immunotherapies (enadenotucirev platform) for solid tumor cancers. Comparable modality (oncolytic adenovirus), target indications (epithelial cancers), and combination immunotherapy strategy.
• DNAtrix: US clinical-stage biotechnology company developing oncolytic virus immunotherapies, primarily for brain cancer (DNX-2401). Comparable modality (oncolytic adenovirus) and immunotherapy combination approach for solid tumors.

Broad incumbents

• Amgen (Imlygic / T-Vec): Large biotech that commercialized talimogene laherparepvec (Imlygic/T-Vec), the first FDA-approved oncolytic virus therapy for melanoma. Established category leader with overlapping modality but different virus backbone (HSV-1) and localized intratumoral delivery versus TILT's intravenous approach.
• Iovance Biotherapeutics: US commercial-stage biotech developing TIL (tumor-infiltrating lymphocyte) cell therapies for solid tumors, including lifileucel for melanoma. Comparable target indications (solid tumors, melanoma, HNSCC) and complementary modality (TILT-123 is designed to combine with TIL therapy per company materials).

Emerging players

• Virogin Biotech: Clinical-stage biotech developing oncolytic viruses (VG161) for solid tumor immunotherapy. Comparable emerging-stage development of cytokine-armed oncolytic virus platform with similar mechanism of action and target indications.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/tilt-biotherapeutics-ltd

Revenue estimate

Valuation estimate

Number of profiles

Profiles14 records

Subsidiaries3 records

Funding overview

Funding rounds10 records

Investors12 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about TILT Biotherapeutics